Outlook Therapeutics annual ebitda margin
2015
2016
2017
2018
2019
2025
Outlook Therapeutics EBITDA Margin Growth & History (OTLK)
Outlook Therapeutics's ebitda margin was −4,735.97% for fiscal 2025.
View full Outlook Therapeutics company overviewOutlook Therapeutics annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-09-30 | −4,735.97% | — |
| 2019 | 2019-09-30 | −404.33% | +456.87 pp |
| 2018 | 2018-09-30 | −861.20% | +9.54 pp |
| 2017 | 2017-09-30 | −870.73% | +772.22 pp |
| 2016 | 2016-09-30 | −1,642.95% | −785.77 pp |
| 2015 | 2015-09-30 | −857.18% | — |
Outlook Therapeutics quarterly ebitda margin
Q2.15
Q3.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q3.25
Q2.26
Q3.26
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q3 2026 | 2026-06-30 | −124,096.76% | −123052.51 pp |
| Q2 2026 | 2026-03-31 | −10,982.96% | — |
| Q3 2025 | 2025-06-30 | −1,044.25% | — |
| Q4 2019 | 2019-09-30 | −201.64% | +1296.53 pp |
| Q3 2019 | 2019-06-30 | −823.98% | +4.88 pp |
| Q2 2019 | 2019-03-31 | −1,074.51% | −281.03 pp |
| Q1 2019 | 2018-12-31 | −883.69% | −559.40 pp |
| Q4 2018 | 2018-09-30 | −1,498.17% | −1420.97 pp |
| Q3 2018 | 2018-06-30 | −828.85% | +1369.57 pp |
| Q2 2018 | 2018-03-31 | −793.47% | +1567.76 pp |
| Q1 2018 | 2017-12-31 | −324.29% | +5325.07 pp |
| Q4 2017 | 2017-09-30 | −77.20% | +1811.87 pp |
| Q3 2017 | 2017-06-30 | −2,198.43% | +2131.57 pp |
| Q2 2017 | 2017-03-31 | −2,361.23% | −2124.44 pp |
| Q1 2017 | 2016-12-31 | −5,649.36% | −4059.31 pp |
| Q4 2016 | 2016-09-30 | −1,889.07% | — |
| Q3 2016 | 2016-06-30 | −4,329.99% | −3509.50 pp |
| Q2 2016 | 2016-03-31 | −236.79% | +2548.18 pp |
| Q1 2016 | 2015-12-31 | −1,590.04% | — |
| Q3 2015 | 2015-06-30 | −820.50% | — |
| Q2 2015 | 2015-03-31 | −2,784.97% | — |
Outlook Therapeutics ebitda margin trends
Between the periods ended 2015-09-30 and 2025-09-30, Outlook Therapeutics's ebitda margin decreased from −857.18% to −4,735.97%, a change of −3878.80 percentage points. The latest reported quarter, Q3 2026, shows −124,096.76%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Outlook Therapeutics source filings ↗